Predictive Oncology Inc is a healthcare technology company focused on advancing personalized medicine through the use of artificial intelligence and machine learning
The company leverages a proprietary platform to analyze and model cancer treatment responses, aiming to provide insights that optimize therapeutic strategies for individual patients. By integrating extensive genomic and clinical data, Predictive Oncology seeks to improve patient outcomes and reduce the time and costs associated with drug development, ultimately enhancing the effectiveness of cancer therapies. Their innovative approach positions them at the forefront of cancer research, contributing to the development of more effective and tailored treatment options.
Company Commits the First Tranche of Financing to Initiate the Integration of AI/ML Platform Technologies, Core Laboratory Capabilities and Business Development Efforts in Europe and the United States
Predictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States
PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQPOAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today closed its previously announced registered direct offering for the purchase and sale of 363,336 shares of common stock at a purchase price of $1.50 per share priced at-the-market under Nasdaq rules.
PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQPOAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today announced that it has entered into definitive agreements for the purchase and sale of 363,336 shares of common stock at a purchase price of $1.50 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about February 19, 2025, subject to the satisfaction of customary closing conditions.
Predictive Oncology stock is trading higher on Tuesday after the company reported positive results from utilizing artificial intelligence for drug repurposing.
Study used Predictive Oncology’s vast biobank of cryopreserved live cell tumor specimens for the production and testing of primary patient tumor spheroids
NEW YORK, Jan. 11, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Predictive Oncology Inc. (NasdaqCM: POAI) to Renovaro Inc. (NasdaqCM: RENB). Under the terms of the binding letter of intent, Predictive Oncology will be merged into Renovaro in exchange for a newly created series of preferred stock of Renovaro. The preferred stock will be issued to shareholders of Predictive Oncology in a 1:1 exchange for their existing Predictive Oncology common stock. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BALA CYNWYD, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Predictive Oncology Inc. (NASDAQPOAI) to Renovaro Inc. is fair to Predictive shareholders.
Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data
- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications –
PITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQPOAI), a leader in AI-driven drug discovery, today announced progress in its ongoing evaluation of strategic alternatives, which was announced on November 13, 2024.
Predictive Oncology (NASDAQPOAI) is announcing participation at the upcoming H.C. Wainwright 26th Annual Global Investment Conference to be held September 9-11 in New York. The company is scheduled to deliver a virtual presentation, which will be available on-demand starting Monday, September 9 at 7 a.m. ET. The Predictive Oncology management team will also host one-on-one meetings during the conference.
PITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQPOAI), a leader in AI-driven drug discovery and biologics, is scheduled to deliver a virtual presentation and host investor one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held September 9th through 11th in New York, NY.
Predictive Oncology (NASDAQPOAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, is reporting on a study that demonstrates the long-term stability and viability of the more than 150,000 cryopreserved patient tumor samples available within its proprietary biobank. According to the report, the study validates highly reproducible drug response data as well as enabling and supporting the AI platform to model and predict patient outcomes on historical samples. The company has released a new white paper that discusses this study, and the importance of tumor sample viability, in greater detail.
